Menu

A Digital Biotech Company

To Research, Design, Develop, Market Digital Therapeutics

We are a Digital Biotech Company devoted to the research, design, development and marketing of prescription digital therapeutics

Our products are based on evidence generated through clinical trials.

Our research areas are mental Health, eating disorders and cardio-metabolic diseases. 

We develop our products following a participatory design approach, involving patients, caregivers and healthcare professionals as partners.

We aim to be a partner of patients and healthcare providers associations, healthcare organizations and institutions to support the development of digital therapeutics in order to offer new hopes for health to patients and more sustainability to healthcare systems

NEWS

EVENTS 2020

Digital Therapeutics Day 2020

Raising awareness about digital therapy, helping to clarify the pathway to reimbursement and integration into healthcare.

September 2020, Rome

« Click here for more info »

#DTxDay2020

Rome, September 2020

Projects

Project daVinci 03
Adult ADHD
To develop a new prescription Digital Therapeutic to treat Adult ADHD as add-on and combination therapy with atomoxetine

Project daVinci 02:
Obesity

Closeup of obese elderly woman
To develop a new prescription Digital Therapeutic to treat Obesity, both as a standalone treatment and combination with a therapist.

Project daVinci 01:
Major Depressive Disorder

Depressed Young Woman Sitting On Bed With Head In Hands
To develop a new prescription Digital Therapeutic to treat Major Depressive Disorder, both as a standalone treatment and combination with a specific antidepressant drug.

Team

massimo-beccaria05

Massimo Beccaria

Co-Founder and CEO
Technical Lead

Engineer from the Politecnico of Milan, with over 15 years of experience in multinational medical device companies and management of advanced technology companies.

giuseppe.recchia

Giuseppe Recchia

Co-Founder and CEO
Development Lead

Medical Doctor, with over 35 years of experience in medical research, development of drugs and advanced technologies in a pharmaceutical company and a scientific foundation

valerio-Rosso

Valerio Rosso

Scientific Consultant - Psychiatry
Clinical Lead

Psychiatrist, expert in Digital Psychiatry and leading Science Blogger, with clinical experience in mental health disorders and skills in advanced digital technology and communication

Partnerships



Argon Global Healthcare, London





USE-ME-D srl, Torino

Twitter

CODE OF ETHICS

We adhere to the DTx Industry Code of Ethics, version November 2019, issued by the Digital Therapeutics Alliance 

  • Demonstrate a commitment to patient safety. Do no harm. Emphasize patient safety as a critical factor in all decision-making processes.

  • Develop interventions that improve the quality of care, clinical outcomes, and quality of life. Develop products that result in a better provision of care and clinical outcomes for patients, caregivers, and the healthcare system.

  • Protect patients’ rights to privacy, consent, and knowledge of data use. Be transparent and accountable about how patientgenerated data is being used, stored, and shared. Selling of identified or de-identified patient data without the patient’s explicit knowledge and consent is prohibited.

  • Directly align the product definition, claims, benefits, and risks with all analytical and clinical evaluation outcomes. The product’s stated intended use and target clinical association must reflect the evidence generated to develop the product definition. DTx products must not make claims greater than what is supported by analytical and clinical evidence.

  • Make claims appropriate to product status within each applicable regulatory jurisdiction. Do not make direct or indirect claims that extend beyond regulatory and legal boundaries established by local authorities.
  • Ensure that credible evidence supporting product claims and outcomes is readily available to patients, caregivers, clinicians, and payors.  Make all trial results inclusive of clinically meaningful outcomes on the stated primary endpoint publicly available.

  • Bring products to market in a responsible way. Respect the end user. Align with DTx Industry Principles and Best Practices. Be forthright about product features, anticipated outcomes, and limitations with relevant stakeholders. Demonstrate a commitment to ongoing testing of product usability, accessibility, sustainability, and reliability.

  • Verify that products perform as expected and deliver on stated claims.  Commit to continuous quality and content improvement through the generation, analysis, and application of real world outcomes, product performance data, and end user feedback.

  • Ensure that product security, data, and functionality are not compromised.  Build an internal culture that prioritizes the protection of data and prevention of security compromise.

  • Maintain a culture of quality and organizational excellence. 
    Prioritize corporate sustainability and human resources to sustain products through every phase of their lifecycle and create long-term value and stability.

Contact Us

Menu

Follow us

Twitter Linkedin Envelope

2019 © daVinci Digital Therapeutics Srl   –   P.IVA 10664440962   –   Privacy